Search research articles
Contact Us
Filters
Showing results (601-610 of 632) with videos related to
Page
of 64
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
March 16, 2013
Development of orally active inhibitors of protein and cellular fucosylation
Nicole M Okeley, Stephen C Alley, Martha E Anderson, et al.
Molecular Pharmacology
|
August 3, 2018
Identification of Positive Allosteric Modulators of the D<sub>1</sub> Dopamine Receptor That Act at Diverse Binding Sites
Kathryn D Luderman, Jennie L Conroy, R Benjamin Free, et al.
British Journal of Haematology
|
July 3, 2026
Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol
N G Mikhaeel, S Bouziana, M Northend, et al.
Journal of Medicinal Chemistry
|
March 19, 2019
Dopamine D<sub>4</sub> Receptor-Selective Compounds Reveal Structure-Activity Relationships that Engender Agonist Efficacy
Thomas M Keck, R Benjamin Free, Marilyn M Day, et al.
Clinical Genetics
|
April 27, 2011
Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene
L Ferri, C Guido, G la Marca, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Orally active fumagillin analogues: transformations of a reactive warhead in the gastric environment
Christopher C Arico-Muendel, Heather Blanchette, Dennis R Benjamin, et al.
IET Systems Biology
|
December 3, 2008
The Alpha Project: a model system for systems biology research
R C Yu, O Resnekov, A P Abola, et al.
Journal of Neurology
|
February 17, 2025
Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)
Barry J Byrne, Benedikt Schoser, Priya S Kishnani, et al.
Journal of Neurology
|
December 6, 2023
Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)
Barry J Byrne, Benedikt Schoser, Priya S Kishnani, et al.
The American Surgeon
|
May 3, 2022
Screening, Brief Intervention, and Referral to Treatment to Prevent Post-Traumatic Stress Disorder After Gunshot Wounds
Christine Castater, Emma Raney, Jonathan Nguyen, et al.
Page
of 64
Search research articles
Search
Showing results (601-610 of 632) with videos related to
Sort By:
Page
of 64
Proceedings of the National Academy of Sciences of the United States of America
|
March 16, 2013
Development of orally active inhibitors of protein and cellular fucosylation
Nicole M Okeley, Stephen C Alley, Martha E Anderson, et al.
Molecular Pharmacology
|
August 3, 2018
Identification of Positive Allosteric Modulators of the D<sub>1</sub> Dopamine Receptor That Act at Diverse Binding Sites
Kathryn D Luderman, Jennie L Conroy, R Benjamin Free, et al.
British Journal of Haematology
|
July 3, 2026
Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol
N G Mikhaeel, S Bouziana, M Northend, et al.
Journal of Medicinal Chemistry
|
March 19, 2019
Dopamine D<sub>4</sub> Receptor-Selective Compounds Reveal Structure-Activity Relationships that Engender Agonist Efficacy
Thomas M Keck, R Benjamin Free, Marilyn M Day, et al.
Clinical Genetics
|
April 27, 2011
Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene
L Ferri, C Guido, G la Marca, et al.
ACS Medicinal Chemistry Letters
|
June 6, 2014
Orally active fumagillin analogues: transformations of a reactive warhead in the gastric environment
Christopher C Arico-Muendel, Heather Blanchette, Dennis R Benjamin, et al.
IET Systems Biology
|
December 3, 2008
The Alpha Project: a model system for systems biology research
R C Yu, O Resnekov, A P Abola, et al.
Journal of Neurology
|
February 17, 2025
Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)
Barry J Byrne, Benedikt Schoser, Priya S Kishnani, et al.
Journal of Neurology
|
December 6, 2023
Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)
Barry J Byrne, Benedikt Schoser, Priya S Kishnani, et al.
The American Surgeon
|
May 3, 2022
Screening, Brief Intervention, and Referral to Treatment to Prevent Post-Traumatic Stress Disorder After Gunshot Wounds
Christine Castater, Emma Raney, Jonathan Nguyen, et al.
Page
of 64